Director/PDMR Shareholding

RNS Number : 5482H

Mediclinic International plc

24 November 2022

 

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

('Mediclinic', or the 'Company', or the 'Group')

24 November 2022

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

This notification sets out details of the vesting of awards over ordinary shares in the Company granted to the executive directors of the Company in respect of the deferred element of the short-term incentive ('STI') scheme pay-out for the financial year ended 31 March 2020 (the 'FY20 STI Awards').

The awards vested on 21 November 2022 and will be settled in cash, based on the closing middle-market quotation of a share on the London Stock Exchange on 21 November 2022, being 495.2 pence per share.

The table below sets out the number of shares vested under the FY20 STI Awards, together with the corresponding cash settlement. The amount settled includes the value of dividends attributable to the vested shares during the period between the date of grant and the date of vesting, being a total of 3.00 pence per share.

Name	Number of shares vested under the FY20 STI Awards	Cash settlement (including dividend equivalents)
Dr Carel Aron van der Merwe ( Group Chief Executive Officer)1	20 391	£101 589
Petrus Jurgens Myburgh ( Group Chief Financial Officer)1	13 383	£66 675

The notifications that follow are made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

1.	Details of person discharging managerial responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Dr Carel Aron van der Merwe
2.	Reason for the notification
a)	Position / status	Group Chief Executive Officer
b)	Initial notification / amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary shares GB00B8HX8Z88
b)	Nature of the transaction	Vesting and cash settlement of award over ordinary shares in Mediclinic International plc granted in 2020 under the Company's STI scheme
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 20 391
d)	Aggregated information Aggregated volume Price	20 391 £nil
e)	Date of the transaction	21 November 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / PCA
a)	Name	Petrus Jurgens Myburgh
2.	Reason for the notification
a)	Position / status	Group Chief Financial Officer
b)	Initial notification / amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary shares GB00B8HX8Z88
b)	Nature of the transaction	Vesting and cash settlement of award over ordinary shares in Mediclinic International plc granted in 2020 under the Company's STI scheme
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 13 383
d)	Aggregated information Aggregated volume Price	13 383 £nil
e)	Date of the transaction	21 November 2022
f)	Place of the transaction	Outside a trading venue

ABOUT MEDICLINIC INTERNATIONAL PLC

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 30 September 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, three mental health facilities, 21 day case clinics and 23 outpatient clinics. Hirslanden operated 17 hospitals and five day case clinics in Switzerland with around 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, three mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract Mediclinic Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ('LSE') in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.7% (2022: 29.9%) interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

CONTACT INFORMATION

Investor queries

James Arnold, Head of Investor Relations, Mediclinic International plc

[phone]

[e-mail] 

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6^th Floor, 65 Gresham Street, London, EC2V 7NQ , United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

 

END

 

 

DSHBUBDBSDDDGDS